Scott, Jemima
Bidulka, Patrick
Taylor, Dominic M.
Udayaraj, Udaya
Caskey, Fergus J.
Birnie, Kate
Deanfield, John
de Belder, Mark
Denaxas, Spiros
Weston, Clive
Adlam, David
Nitsch, Dorothea
Funding for this research was provided by:
National Institute for Health and Care Research (300906)
Health Foundation, UK (1725841, 1725841)
Article History
Received: 10 May 2023
Accepted: 23 October 2023
First Online: 2 November 2023
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. This study was approved by the London School of Hygiene & Tropical Medicine LEO ethics committee (ID 16988) and the National Chronic Kidney Disease Audit (NCKDA) Steering Committee. Audits used in this study are covered by Section 251 approvals (NHS Act 2006) which allows data to be collected without individual patient consent for medical research when it is not possible to use anonymised information and when seeking consent is not practical.
: Not applicable.
: All authors have completed an ICJME form. PB, DMT, FJC, KB, MDB, and SD have nothing to declare. UU declares a grant from the Health Foundation to undertake quality improvement unrelated to this work. MS declares funding from Cancer Research UK (C53325/A21134) and British Heart Foundation (SP/16/5/32415) for research activities related to this work looking at acute myocardial infarction ascertainment in a cancer population. JS declares Doctoral research funding from the NIHR for related research looking at acute myocardial infarction care for people with chronic kidney disease. JD declares grants from British Heart Foundation paid to his institution unrelated to this work. JD also declares consulting fees from Novo Nordisk, and honoraria from Amgen, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi, Takeda, Novo Nordisk, and Bayer, unrelated to this work. JD is also member of a study steering committee with Novo Nordisk. CW declares he is clinical lead of the Myocardial Ischaemia National Audit Project. DA reports research funding and in-kind support from Astra Zeneca inc. for unrelated research and educational funding from Abbott Vascular inc. to support a clinical research fellow doing unrelated research. DA has conducted consultancy for General Electric inc. to support general research funds. DN is the UK Kidney Association Director of Informatics Research. DN is also on the steering group for two GlaxoSmithKline funded studies that investigate kidney function in children and adults in Sub-Saharan Africa.